Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming
Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiov...
Saved in:
| Published in | Redox biology Vol. 73; p. 103183 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.07.2024
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2213-2317 2213-2317 |
| DOI | 10.1016/j.redox.2024.103183 |
Cover
| Abstract | Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved.
A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models.
SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention.
[Display omitted] |
|---|---|
| AbstractList | Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved.AIMSVascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved.A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models.METHODS AND RESULTSA computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models.SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention.CONCLUSIONSSGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention. Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved. A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models. SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention. Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved. A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models. SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention. [Display omitted] Aims: Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved. Methods and results: A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models. Conclusions: SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention. |
| ArticleNumber | 103183 |
| Author | Liu, Chuan Luo, Xiaolin Qin, Zhexue Chen, Yang Luo, Wenjian Wang, Zelan Zhang, Jiawen Wu, Shaofa Sun, Ning Huang, Lan Liu, Xi Tong, Xiaoyong Zhao, Junyong |
| Author_xml | – sequence: 1 givenname: Shaofa surname: Wu fullname: Wu, Shaofa organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 2 givenname: Xiaolin surname: Luo fullname: Luo, Xiaolin organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 3 givenname: Yang surname: Chen fullname: Chen, Yang organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 4 givenname: Zelan surname: Wang fullname: Wang, Zelan organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 5 givenname: Xi surname: Liu fullname: Liu, Xi organization: Department of Nephrology, Youyang Hospital, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 409800, China – sequence: 6 givenname: Ning surname: Sun fullname: Sun, Ning organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 7 givenname: Junyong surname: Zhao fullname: Zhao, Junyong organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 8 givenname: Wenjian surname: Luo fullname: Luo, Wenjian organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 9 givenname: Jiawen surname: Zhang fullname: Zhang, Jiawen organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 10 givenname: Xiaoyong surname: Tong fullname: Tong, Xiaoyong organization: Innovative Drug Research Centre, Chongqing University, Chongqing, 401331, China – sequence: 11 givenname: Lan surname: Huang fullname: Huang, Lan email: huanglan260@126.com organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 12 givenname: Chuan surname: Liu fullname: Liu, Chuan email: liuchuan19821207@163.com organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China – sequence: 13 givenname: Zhexue orcidid: 0000-0001-7943-1361 surname: Qin fullname: Qin, Zhexue email: zhexueqin@126.com organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38759418$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks1u1DAUhSNURMvQJ0BCXrLJYDt_9oIFqvipVIkFsLZu7JupR4kdbKcwr8bT4ZmUCrEAvLnW1fmOfO_x0-LMeYdF8ZzRLaOsfbXfBjT--5ZTXudOxUT1qLjgnFUlr1h39tv9vLiMcU_zEaLmjD4pzivRNbJm4qL48ckbu0zlbly0j0i0TwFcnH1IGAgn1t3a3iYfIoGU0C2QkNxB1MsIgWgYtR2shmS9I_2BxGWeA8Zo3Y6gM34eIU5Wk4DJZmSZyBx8QutIurX-NEK-Gz9BLtq7lOuRbYjBORugS8THhH6H7mST8V2AacqiZ8XjAcaIl_d1U3x59_bz1Yfy5uP766s3N6WuO5pKbiiABAFV3_fCcAnQNbxrJWe9QGgQ6r4G3lcoepRtrnKoqQbZZ55rUW2K69XXeNirOdgJwkF5sOrU8GGnIOTxRlQdGMlp1aIUtGYIYBpp9DBoVmNHTZe96tVrcTMcvsE4Phgyqo7Jqr06rUUdk1Vrshl7uWJ5_K8LxqQmGzWOIzj0S1QVbdq27WSWb4oX99Kln9A82P-KPAuqVaCDjzHg8J8vkH9Q2qZT7Pm_2PEf7OuVxZzSncWgorboNBobUKe8RvtX_ifgVvFg |
| CitedBy_id | crossref_primary_10_1002_advs_202410495 crossref_primary_10_3390_ijms26052103 crossref_primary_10_3389_fphar_2024_1510030 crossref_primary_10_1186_s12933_024_02368_y crossref_primary_10_4330_wjc_v17_i1_101491 crossref_primary_10_3390_ijms251810225 crossref_primary_10_3390_ijms26041670 crossref_primary_10_1007_s11302_024_10045_8 crossref_primary_10_1016_j_cpcardiol_2024_102951 |
| Cites_doi | 10.1038/cmi.2017.20 10.1159/000159247 10.1016/j.atherosclerosis.2018.02.028 10.1056/NEJMoa1911303 10.1161/CIRCRESAHA.112.267237 10.3390/ijms22020818 10.1007/s00210-023-02627-x 10.1161/CIRCRESAHA.121.320251 10.3390/ijms151223501 10.1161/ATVBAHA.119.312659 10.1152/ajpendo.00053.2009 10.1093/cvr/cvad119 10.1146/annurev-physiol-031620-095920 10.1093/eurheartj/ehad192 10.1161/CIRCRESAHA.117.312130 10.1038/s41401-023-01217-0 10.1016/j.lfs.2020.117389 10.1136/gutjnl-2021-325065 10.1016/S0140-6736(18)32590-X 10.1186/s12933-019-0903-4 10.1038/s41588-019-0514-8 10.1038/s41467-020-18047-x 10.1186/s12933-018-0749-1 10.1172/JCI143645 10.1161/01.CIR.92.8.2029 10.1002/sim.3697 10.1007/s00210-023-02607-1 10.1093/eurheartj/ehad195 10.1056/NEJMoa1504720 10.1172/JCI117205 10.1161/ATVBAHA.120.313131 10.1093/cvr/cvad133 10.1161/CIRCRESAHA.121.319745 10.1126/sciadv.abl8096 10.1038/s41591-022-01703-8 10.1172/JCI116391 10.2131/jts.23.5_433 10.3390/ijms21062204 10.1161/JAHA.113.000238 10.2337/db20-0840 10.1016/j.tcm.2014.10.021 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2024 The Authors – notice: Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY DOA |
| DOI | 10.1016/j.redox.2024.103183 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2213-2317 |
| ExternalDocumentID | oai_doaj_org_article_7ad92036e98041eaad59dcffc14e70d7 10.1016/j.redox.2024.103183 38759418 10_1016_j_redox_2024_103183 S2213231724001617 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 0SF 457 53G 5VS 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAXUO ABGSF ABMAC ACGFS ADBBV ADEZE ADRAZ ADUVX AENEX AEXQZ AFTJW AGHFR AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BAWUL BCNDV DIK EBS EJD FDB GROUPED_DOAJ HYE HZ~ IPNFZ IXB M48 MO0 M~E NCXOZ O-L O9- OK1 RIG ROL RPM SSZ AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AKBMS AKYEP APXCP CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c470t-2d0aa9a8a3bbb8d29aa75276921b8ea5ea4b4a2b3e8be96b3e9f40ca9bc472c83 |
| IEDL.DBID | M48 |
| ISSN | 2213-2317 |
| IngestDate | Fri Oct 03 12:53:40 EDT 2025 Sun Oct 26 03:03:53 EDT 2025 Thu Oct 02 03:55:26 EDT 2025 Mon Jul 21 06:02:07 EDT 2025 Thu Apr 24 23:07:37 EDT 2025 Tue Jul 01 00:47:13 EDT 2025 Tue Jun 18 08:51:25 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Vascular calcification Thioredoxin domain containing 5 Sodium-glucose cotransporter 2 inhibitors Runx2 Endoplasmic reticulum stress |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. cc-by-nc-nd |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c470t-2d0aa9a8a3bbb8d29aa75276921b8ea5ea4b4a2b3e8be96b3e9f40ca9bc472c83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-7943-1361 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://doi.org/10.1016/j.redox.2024.103183 |
| PMID | 38759418 |
| PQID | 3056667910 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7ad92036e98041eaad59dcffc14e70d7 unpaywall_primary_10_1016_j_redox_2024_103183 proquest_miscellaneous_3056667910 pubmed_primary_38759418 crossref_primary_10_1016_j_redox_2024_103183 crossref_citationtrail_10_1016_j_redox_2024_103183 elsevier_sciencedirect_doi_10_1016_j_redox_2024_103183 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | July 2024 2024-07-00 2024-Jul 20240701 2024-07-01 |
| PublicationDateYYYYMMDD | 2024-07-01 |
| PublicationDate_xml | – month: 07 year: 2024 text: July 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Redox biology |
| PublicationTitleAlternate | Redox Biol |
| PublicationYear | 2024 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Yang, Dai, Wu (bib34) 2022; 130 Watson, Bostrom, Ravindranath, Lam, Norton, Demer (bib4) 1994; 93 Zelniker, Wiviott, Raz (bib43) 2019; 393 Wang, Dong, Song, Zhang, Pan, Han (bib15) 2018; 15 Spertus, Birmingham, Nassif (bib8) 2022; 28 Bostrom, Watson, Horn, Wortham, Herman, Demer (bib3) 1993; 91 Austin (bib21) 2009; 28 Liu, Chen, Li (bib32) 2023; 119 Zinman, Wanner, Lachin (bib6) 2015; 373 Horna-Terron, Pradilla-Dieste, Sanchez-de-Diego, Osada (bib12) 2014; 15 Shih, Chen, Zhang (bib13) 2018; 122 Ortega, Collado, Selles (bib20) 2019; 39 Dai, Liu, Cheng (bib25) 2022; 130 Vallon, Verma (bib40) 2021; 83 Sun, Byon, Yuan (bib5) 2012; 111 McDonagh, Metra, Adamo (bib42) 2023; 44 Marx, Federici, Schutt (bib41) 2023; 44 Kluger, Tecson, Lee (bib27) 2019; 18 Lee, Yeh, Lee (bib38) 2020; 11 Campeau, Leask (bib11) 2024; 397 McMurray, Solomon, Inzucchi (bib7) 2019; 381 Al-Sharea, Murphy, Huggins, Hu, Goldberg, Nagareddy (bib22) 2018; 271 Leopold (bib1) 2015; 25 Yeh, Cheng, Lin (bib16) 2022; 8 Masuda, Miyazaki-Anzai, Levi, Ting, Miyazaki (bib33) 2013; 2 Chen, Zhao, Wu (bib24) 2020; 40 Lu, Lee, Hsieh, Hsu (bib29) 2023; 24 Nasiri-Ansari, Nikolopoulou, Papoutsi (bib36) 2021; 22 Malhotra, Mauer, Lino Cardenas (bib26) 2019; 51 Chen, Lan, Li (bib9) 2023; 119 Niederhoffer, Bobryshev, Lartaud-Idjouadiene, Giummelly, Atkinson (bib17) 1997; 34 Sun, Byon, Yuan (bib30) 2012; 111 Herrmann, Babic, Tolle, van der Giet, Schuchardt (bib18) 2020; 21 Demer (bib2) 1995; 92 Li, Chen, Sun, Yang, Jin, Liu (bib10) 2024; 45 Nasiri-Ansari, Dimitriadis, Agrogiannis (bib23) 2018; 17 Hung, Su, Chen (bib14) 2022; 71 Barata, Yoshida, Hokao, Maekawa (bib19) 1998; 23 Hewedy, Abdulmalek, Ghareeb, Habiba (bib28) 2024; 397 Shih, Lin, Fisch (bib35) 2021; 70 Alberti, Karamessinis, Peroulis (bib37) 2009; 297 Gomathi, Akshaya, Srinaath, Moorthi, Selvamurugan (bib31) 2020; 245 Chen, Jhao, Hung (bib39) 2021; 131 McDonagh (10.1016/j.redox.2024.103183_bib42) 2023; 44 Zinman (10.1016/j.redox.2024.103183_bib6) 2015; 373 Austin (10.1016/j.redox.2024.103183_bib21) 2009; 28 Barata (10.1016/j.redox.2024.103183_bib19) 1998; 23 Masuda (10.1016/j.redox.2024.103183_bib33) 2013; 2 Wang (10.1016/j.redox.2024.103183_bib15) 2018; 15 Demer (10.1016/j.redox.2024.103183_bib2) 1995; 92 Zelniker (10.1016/j.redox.2024.103183_bib43) 2019; 393 Sun (10.1016/j.redox.2024.103183_bib30) 2012; 111 Yang (10.1016/j.redox.2024.103183_bib34) 2022; 130 Marx (10.1016/j.redox.2024.103183_bib41) 2023; 44 Alberti (10.1016/j.redox.2024.103183_bib37) 2009; 297 Dai (10.1016/j.redox.2024.103183_bib25) 2022; 130 Bostrom (10.1016/j.redox.2024.103183_bib3) 1993; 91 Gomathi (10.1016/j.redox.2024.103183_bib31) 2020; 245 Vallon (10.1016/j.redox.2024.103183_bib40) 2021; 83 Yeh (10.1016/j.redox.2024.103183_bib16) 2022; 8 Chen (10.1016/j.redox.2024.103183_bib39) 2021; 131 Niederhoffer (10.1016/j.redox.2024.103183_bib17) 1997; 34 Lu (10.1016/j.redox.2024.103183_bib29) 2023; 24 Hewedy (10.1016/j.redox.2024.103183_bib28) 2024; 397 Horna-Terron (10.1016/j.redox.2024.103183_bib12) 2014; 15 Nasiri-Ansari (10.1016/j.redox.2024.103183_bib23) 2018; 17 Kluger (10.1016/j.redox.2024.103183_bib27) 2019; 18 Chen (10.1016/j.redox.2024.103183_bib9) 2023; 119 Chen (10.1016/j.redox.2024.103183_bib24) 2020; 40 Spertus (10.1016/j.redox.2024.103183_bib8) 2022; 28 Leopold (10.1016/j.redox.2024.103183_bib1) 2015; 25 McMurray (10.1016/j.redox.2024.103183_bib7) 2019; 381 Malhotra (10.1016/j.redox.2024.103183_bib26) 2019; 51 Lee (10.1016/j.redox.2024.103183_bib38) 2020; 11 Sun (10.1016/j.redox.2024.103183_bib5) 2012; 111 Liu (10.1016/j.redox.2024.103183_bib32) 2023; 119 Shih (10.1016/j.redox.2024.103183_bib13) 2018; 122 Ortega (10.1016/j.redox.2024.103183_bib20) 2019; 39 Campeau (10.1016/j.redox.2024.103183_bib11) 2024; 397 Herrmann (10.1016/j.redox.2024.103183_bib18) 2020; 21 Nasiri-Ansari (10.1016/j.redox.2024.103183_bib36) 2021; 22 Watson (10.1016/j.redox.2024.103183_bib4) 1994; 93 Hung (10.1016/j.redox.2024.103183_bib14) 2022; 71 Al-Sharea (10.1016/j.redox.2024.103183_bib22) 2018; 271 Li (10.1016/j.redox.2024.103183_bib10) 2024; 45 Shih (10.1016/j.redox.2024.103183_bib35) 2021; 70 |
| References_xml | – volume: 51 start-page: 1580 year: 2019 end-page: 1587 ident: bib26 article-title: HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype publication-title: Nat. Genet. – volume: 245 year: 2020 ident: bib31 article-title: Regulation of Runx2 by post-translational modifications in osteoblast differentiation publication-title: Life Sci. – volume: 28 start-page: 809 year: 2022 end-page: 813 ident: bib8 article-title: The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial publication-title: Nat. Med. – volume: 297 start-page: E812 year: 2009 end-page: E821 ident: bib37 article-title: ERp46 is reduced by high glucose and regulates insulin content in pancreatic beta-cells publication-title: Am. J. Physiol. Endocrinol. Metab. – volume: 91 start-page: 1800 year: 1993 end-page: 1809 ident: bib3 article-title: Bone morphogenetic protein expression in human atherosclerotic lesions publication-title: J. Clin. Invest. – volume: 44 start-page: 4043 year: 2023 end-page: 4140 ident: bib41 article-title: ESC Guidelines for the management of cardiovascular disease in patients with diabetes publication-title: Eur. Heart J. – volume: 381 start-page: 1995 year: 2019 end-page: 2008 ident: bib7 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction publication-title: N. Engl. J. Med. – volume: 22 start-page: 818 year: 2021 ident: bib36 article-title: Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE((-/-)) mice by activating autophagy and reducing ER stress and apoptosis publication-title: Int. J. Mol. Sci. – volume: 393 start-page: 31 year: 2019 end-page: 39 ident: bib43 article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials publication-title: Lancet – volume: 111 start-page: 543 year: 2012 end-page: 552 ident: bib5 article-title: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification publication-title: Circ. Res. – volume: 122 start-page: 1052 year: 2018 end-page: 1068 ident: bib13 article-title: Endoplasmic reticulum protein TXNDC5 augments myocardial fibrosis by facilitating extracellular matrix protein folding and redox-sensitive cardiac fibroblast activation publication-title: Circ. Res. – volume: 15 start-page: 685 year: 2018 end-page: 696 ident: bib15 article-title: TXNDC5 synergizes with HSC70 to exacerbate the inflammatory phenotype of synovial fibroblasts in rheumatoid arthritis through NF-kappaB signaling publication-title: Cell. Mol. Immunol. – volume: 45 start-page: 751 year: 2024 end-page: 764 ident: bib10 article-title: Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation publication-title: Acta Pharmacol. Sin. – volume: 23 start-page: 433 year: 1998 end-page: 442 ident: bib19 article-title: Sequential alterations in clinical biochemical indicators of renal function in 5/6 nephrectomized rats--basic study for renal toxicity using 5/6 nephrectomized rats publication-title: J. Toxicol. Sci. – volume: 28 start-page: 3083 year: 2009 end-page: 3107 ident: bib21 article-title: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples publication-title: Stat. Med. – volume: 111 start-page: 543 year: 2012 end-page: 552 ident: bib30 article-title: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification publication-title: Circ. Res. – volume: 21 start-page: 2204 year: 2020 ident: bib18 article-title: Research models for studying vascular calcification publication-title: Int. J. Mol. Sci. – volume: 130 start-page: 1565 year: 2022 end-page: 1582 ident: bib25 article-title: Epigenetic upregulation of H19 and AMPK inhibition concurrently contribute to S-adenosylhomocysteine hydrolase deficiency-promoted atherosclerotic calcification publication-title: Circ. Res. – volume: 93 start-page: 2106 year: 1994 end-page: 2113 ident: bib4 article-title: TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify publication-title: J. Clin. Invest. – volume: 18 start-page: 99 year: 2019 ident: bib27 article-title: Class effects of SGLT2 inhibitors on cardiorenal outcomes publication-title: Cardiovasc. Diabetol. – volume: 39 start-page: 1614 year: 2019 end-page: 1628 ident: bib20 article-title: SGLT-2 (Sodium-Glucose cotransporter 2) inhibition reduces ang II (angiotensin II)-Induced dissecting abdominal aortic aneurysm in ApoE (apolipoprotein E) knockout mice publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 34 start-page: 386 year: 1997 end-page: 398 ident: bib17 article-title: Aortic calcification produced by vitamin D3 plus nicotine publication-title: J. Vasc. Res. – volume: 17 start-page: 106 year: 2018 ident: bib23 article-title: Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice publication-title: Cardiovasc. Diabetol. – volume: 397 start-page: 873 year: 2024 end-page: 888 ident: bib28 article-title: AMPK-mediated autophagy is involved in the protective effect of canagliflozin in the vitamin D3 plus nicotine calcification model in rats publication-title: Naunyn-Schmiedeberg’s Arch. Pharmacol. – volume: 373 start-page: 2117 year: 2015 end-page: 2128 ident: bib6 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes publication-title: N. Engl. J. Med. – volume: 71 start-page: 1876 year: 2022 end-page: 1891 ident: bib14 article-title: Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling publication-title: Gut – volume: 131 year: 2021 ident: bib39 article-title: Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-beta signaling in kidney fibroblasts publication-title: J. Clin. Invest. – volume: 83 start-page: 503 year: 2021 end-page: 528 ident: bib40 article-title: Effects of SGLT2 inhibitors on kidney and cardiovascular function publication-title: Annu. Rev. Physiol. – volume: 15 start-page: 23501 year: 2014 end-page: 23518 ident: bib12 article-title: TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology publication-title: Int. J. Mol. Sci. – volume: 92 start-page: 2029 year: 1995 end-page: 2032 ident: bib2 article-title: A skeleton in the atherosclerosis closet publication-title: Circulation – volume: 24 year: 2023 ident: bib29 article-title: Empagliflozin attenuates vascular calcification in mice with chronic kidney disease by regulating the NFR2/HO-1 anti-inflammatory pathway through AMPK activation publication-title: Int. J. Mol. Sci. – volume: 40 start-page: 1078 year: 2020 end-page: 1093 ident: bib24 article-title: Arterial stiffness: a focus on vascular calcification and its link to bone mineralization publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 25 start-page: 267 year: 2015 end-page: 274 ident: bib1 article-title: Vascular calcification: mechanisms of vascular smooth muscle cell calcification publication-title: Trends Cardiovasc. Med. – volume: 130 start-page: 213 year: 2022 end-page: 229 ident: bib34 article-title: Unspliced XBP1 counteracts beta-catenin to inhibit vascular calcification publication-title: Circ. Res. – volume: 8 year: 2022 ident: bib16 article-title: Targeting mechanosensitive endothelial TXNDC5 to stabilize eNOS and reduce atherosclerosis in vivo publication-title: Sci. Adv. – volume: 119 start-page: 2563 year: 2023 end-page: 2578 ident: bib32 article-title: C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification via PERK-eIF2alpha-ATF4-CREB3L1 pathway publication-title: Cardiovasc. Res. – volume: 44 start-page: 3627 year: 2023 end-page: 3639 ident: bib42 article-title: Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure publication-title: Eur. Heart J. – volume: 11 start-page: 4254 year: 2020 ident: bib38 article-title: Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFbeta signaling through TGFBR1 stabilization publication-title: Nat. Commun. – volume: 271 start-page: 166 year: 2018 end-page: 176 ident: bib22 article-title: SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-/-) type 1 diabetic mice publication-title: Atherosclerosis – volume: 2 year: 2013 ident: bib33 article-title: PERK-eIF2alpha-ATF4-CHOP signaling contributes to TNFalpha-induced vascular calcification publication-title: J. Am. Heart Assoc. – volume: 119 start-page: 2368 year: 2023 end-page: 2381 ident: bib9 article-title: Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome publication-title: Cardiovasc. Res. – volume: 70 start-page: 262 year: 2021 end-page: 267 ident: bib35 article-title: Dapagliflozin suppresses ER stress and improves subclinical myocardial function in diabetes: from bedside to bench publication-title: Diabetes – volume: 397 start-page: 267 year: 2024 end-page: 279 ident: bib11 article-title: Empagliflozin reduces endoplasmic reticulum stress associated TXNIP/NLRP3 activation in tunicamycin-stimulated aortic endothelial cells publication-title: Naunyn-Schmiedeberg’s Arch. Pharmacol. – volume: 15 start-page: 685 year: 2018 ident: 10.1016/j.redox.2024.103183_bib15 article-title: TXNDC5 synergizes with HSC70 to exacerbate the inflammatory phenotype of synovial fibroblasts in rheumatoid arthritis through NF-kappaB signaling publication-title: Cell. Mol. Immunol. doi: 10.1038/cmi.2017.20 – volume: 34 start-page: 386 year: 1997 ident: 10.1016/j.redox.2024.103183_bib17 article-title: Aortic calcification produced by vitamin D3 plus nicotine publication-title: J. Vasc. Res. doi: 10.1159/000159247 – volume: 271 start-page: 166 year: 2018 ident: 10.1016/j.redox.2024.103183_bib22 article-title: SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-/-) type 1 diabetic mice publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2018.02.028 – volume: 381 start-page: 1995 year: 2019 ident: 10.1016/j.redox.2024.103183_bib7 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1911303 – volume: 111 start-page: 543 year: 2012 ident: 10.1016/j.redox.2024.103183_bib5 article-title: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.112.267237 – volume: 22 start-page: 818 year: 2021 ident: 10.1016/j.redox.2024.103183_bib36 article-title: Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE((-/-)) mice by activating autophagy and reducing ER stress and apoptosis publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms22020818 – volume: 397 start-page: 873 year: 2024 ident: 10.1016/j.redox.2024.103183_bib28 article-title: AMPK-mediated autophagy is involved in the protective effect of canagliflozin in the vitamin D3 plus nicotine calcification model in rats publication-title: Naunyn-Schmiedeberg’s Arch. Pharmacol. doi: 10.1007/s00210-023-02627-x – volume: 130 start-page: 1565 year: 2022 ident: 10.1016/j.redox.2024.103183_bib25 article-title: Epigenetic upregulation of H19 and AMPK inhibition concurrently contribute to S-adenosylhomocysteine hydrolase deficiency-promoted atherosclerotic calcification publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.121.320251 – volume: 15 start-page: 23501 year: 2014 ident: 10.1016/j.redox.2024.103183_bib12 article-title: TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms151223501 – volume: 39 start-page: 1614 year: 2019 ident: 10.1016/j.redox.2024.103183_bib20 article-title: SGLT-2 (Sodium-Glucose cotransporter 2) inhibition reduces ang II (angiotensin II)-Induced dissecting abdominal aortic aneurysm in ApoE (apolipoprotein E) knockout mice publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.119.312659 – volume: 297 start-page: E812 year: 2009 ident: 10.1016/j.redox.2024.103183_bib37 article-title: ERp46 is reduced by high glucose and regulates insulin content in pancreatic beta-cells publication-title: Am. J. Physiol. Endocrinol. Metab. doi: 10.1152/ajpendo.00053.2009 – volume: 119 start-page: 2368 year: 2023 ident: 10.1016/j.redox.2024.103183_bib9 article-title: Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome publication-title: Cardiovasc. Res. doi: 10.1093/cvr/cvad119 – volume: 83 start-page: 503 year: 2021 ident: 10.1016/j.redox.2024.103183_bib40 article-title: Effects of SGLT2 inhibitors on kidney and cardiovascular function publication-title: Annu. Rev. Physiol. doi: 10.1146/annurev-physiol-031620-095920 – volume: 44 start-page: 4043 year: 2023 ident: 10.1016/j.redox.2024.103183_bib41 article-title: ESC Guidelines for the management of cardiovascular disease in patients with diabetes publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehad192 – volume: 122 start-page: 1052 year: 2018 ident: 10.1016/j.redox.2024.103183_bib13 article-title: Endoplasmic reticulum protein TXNDC5 augments myocardial fibrosis by facilitating extracellular matrix protein folding and redox-sensitive cardiac fibroblast activation publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.117.312130 – volume: 45 start-page: 751 year: 2024 ident: 10.1016/j.redox.2024.103183_bib10 article-title: Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation publication-title: Acta Pharmacol. Sin. doi: 10.1038/s41401-023-01217-0 – volume: 245 year: 2020 ident: 10.1016/j.redox.2024.103183_bib31 article-title: Regulation of Runx2 by post-translational modifications in osteoblast differentiation publication-title: Life Sci. doi: 10.1016/j.lfs.2020.117389 – volume: 71 start-page: 1876 year: 2022 ident: 10.1016/j.redox.2024.103183_bib14 article-title: Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling publication-title: Gut doi: 10.1136/gutjnl-2021-325065 – volume: 393 start-page: 31 year: 2019 ident: 10.1016/j.redox.2024.103183_bib43 article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials publication-title: Lancet doi: 10.1016/S0140-6736(18)32590-X – volume: 18 start-page: 99 year: 2019 ident: 10.1016/j.redox.2024.103183_bib27 article-title: Class effects of SGLT2 inhibitors on cardiorenal outcomes publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-019-0903-4 – volume: 51 start-page: 1580 year: 2019 ident: 10.1016/j.redox.2024.103183_bib26 article-title: HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype publication-title: Nat. Genet. doi: 10.1038/s41588-019-0514-8 – volume: 11 start-page: 4254 year: 2020 ident: 10.1016/j.redox.2024.103183_bib38 article-title: Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFbeta signaling through TGFBR1 stabilization publication-title: Nat. Commun. doi: 10.1038/s41467-020-18047-x – volume: 17 start-page: 106 year: 2018 ident: 10.1016/j.redox.2024.103183_bib23 article-title: Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-018-0749-1 – volume: 131 year: 2021 ident: 10.1016/j.redox.2024.103183_bib39 article-title: Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-beta signaling in kidney fibroblasts publication-title: J. Clin. Invest. doi: 10.1172/JCI143645 – volume: 92 start-page: 2029 year: 1995 ident: 10.1016/j.redox.2024.103183_bib2 article-title: A skeleton in the atherosclerosis closet publication-title: Circulation doi: 10.1161/01.CIR.92.8.2029 – volume: 28 start-page: 3083 year: 2009 ident: 10.1016/j.redox.2024.103183_bib21 article-title: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples publication-title: Stat. Med. doi: 10.1002/sim.3697 – volume: 397 start-page: 267 year: 2024 ident: 10.1016/j.redox.2024.103183_bib11 article-title: Empagliflozin reduces endoplasmic reticulum stress associated TXNIP/NLRP3 activation in tunicamycin-stimulated aortic endothelial cells publication-title: Naunyn-Schmiedeberg’s Arch. Pharmacol. doi: 10.1007/s00210-023-02607-1 – volume: 44 start-page: 3627 year: 2023 ident: 10.1016/j.redox.2024.103183_bib42 article-title: Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehad195 – volume: 373 start-page: 2117 year: 2015 ident: 10.1016/j.redox.2024.103183_bib6 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1504720 – volume: 111 start-page: 543 year: 2012 ident: 10.1016/j.redox.2024.103183_bib30 article-title: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.112.267237 – volume: 93 start-page: 2106 year: 1994 ident: 10.1016/j.redox.2024.103183_bib4 article-title: TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify publication-title: J. Clin. Invest. doi: 10.1172/JCI117205 – volume: 40 start-page: 1078 year: 2020 ident: 10.1016/j.redox.2024.103183_bib24 article-title: Arterial stiffness: a focus on vascular calcification and its link to bone mineralization publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.120.313131 – volume: 119 start-page: 2563 year: 2023 ident: 10.1016/j.redox.2024.103183_bib32 article-title: C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification via PERK-eIF2alpha-ATF4-CREB3L1 pathway publication-title: Cardiovasc. Res. doi: 10.1093/cvr/cvad133 – volume: 130 start-page: 213 year: 2022 ident: 10.1016/j.redox.2024.103183_bib34 article-title: Unspliced XBP1 counteracts beta-catenin to inhibit vascular calcification publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.121.319745 – volume: 8 year: 2022 ident: 10.1016/j.redox.2024.103183_bib16 article-title: Targeting mechanosensitive endothelial TXNDC5 to stabilize eNOS and reduce atherosclerosis in vivo publication-title: Sci. Adv. doi: 10.1126/sciadv.abl8096 – volume: 28 start-page: 809 year: 2022 ident: 10.1016/j.redox.2024.103183_bib8 article-title: The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial publication-title: Nat. Med. doi: 10.1038/s41591-022-01703-8 – volume: 91 start-page: 1800 year: 1993 ident: 10.1016/j.redox.2024.103183_bib3 article-title: Bone morphogenetic protein expression in human atherosclerotic lesions publication-title: J. Clin. Invest. doi: 10.1172/JCI116391 – volume: 24 year: 2023 ident: 10.1016/j.redox.2024.103183_bib29 article-title: Empagliflozin attenuates vascular calcification in mice with chronic kidney disease by regulating the NFR2/HO-1 anti-inflammatory pathway through AMPK activation publication-title: Int. J. Mol. Sci. – volume: 23 start-page: 433 year: 1998 ident: 10.1016/j.redox.2024.103183_bib19 article-title: Sequential alterations in clinical biochemical indicators of renal function in 5/6 nephrectomized rats--basic study for renal toxicity using 5/6 nephrectomized rats publication-title: J. Toxicol. Sci. doi: 10.2131/jts.23.5_433 – volume: 21 start-page: 2204 year: 2020 ident: 10.1016/j.redox.2024.103183_bib18 article-title: Research models for studying vascular calcification publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms21062204 – volume: 2 year: 2013 ident: 10.1016/j.redox.2024.103183_bib33 article-title: PERK-eIF2alpha-ATF4-CHOP signaling contributes to TNFalpha-induced vascular calcification publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.113.000238 – volume: 70 start-page: 262 year: 2021 ident: 10.1016/j.redox.2024.103183_bib35 article-title: Dapagliflozin suppresses ER stress and improves subclinical myocardial function in diabetes: from bedside to bench publication-title: Diabetes doi: 10.2337/db20-0840 – volume: 25 start-page: 267 year: 2015 ident: 10.1016/j.redox.2024.103183_bib1 article-title: Vascular calcification: mechanisms of vascular smooth muscle cell calcification publication-title: Trends Cardiovasc. Med. doi: 10.1016/j.tcm.2014.10.021 |
| SSID | ssj0000884210 |
| Score | 2.4168806 |
| Snippet | Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose... Aims: Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose... |
| SourceID | doaj unpaywall proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 103183 |
| SubjectTerms | Animals Benzhydryl Compounds - pharmacology Core Binding Factor Alpha 1 Subunit - genetics Core Binding Factor Alpha 1 Subunit - metabolism Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Disease Models, Animal Endoplasmic Reticulum - drug effects Endoplasmic Reticulum - metabolism Endoplasmic reticulum stress Endoplasmic Reticulum Stress - drug effects Female Glucosides - pharmacology Humans Male Mice Muscle, Smooth, Vascular - cytology Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - metabolism Muscle, Smooth, Vascular - pathology Myocytes, Smooth Muscle - drug effects Myocytes, Smooth Muscle - metabolism Osteogenesis - drug effects Rats Runx2 Sodium-glucose cotransporter 2 inhibitors Sodium-Glucose Transporter 2 Inhibitors - pharmacology Thioredoxin domain containing 5 Thioredoxins - genetics Thioredoxins - metabolism Vascular calcification Vascular Calcification - drug therapy Vascular Calcification - etiology Vascular Calcification - metabolism Vascular Calcification - pathology |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQJQQcEN-kFGQkjkQkjpPYx1JRVUhwgUq9WePYoUG7zqpNBPvX-us6tpNoK6TCgVNWK8cb77ys32zevCHkHTe2LjCcKfPiMA55m4LVVdqWmS7yUhem9IXCX75WJ6f881l5ttPqy2vCoj1w_OI-1GCkf1hmpXfKsQCmlKZp2ybnts5MqCPPhNxJpsJvsBAck5nZZigIurwB52_MCBn3lea5KG5sRcGx_8aO9CfjfEDujW4D21-wWu3sQsePyMOJPtLDeNmPyR3rnpC7saHk9im5-tabblzPQnTa9MNiXn5BGe3ceac732CHel9NNyLTpLMYlWK4gkIvBIvqLb0cN1En635Q60y_Qaq97hoaKh_934Y02Dx0jg7nXR9Wjq9NvwY8eBF8bD9BSzr32h2oLyrpEbVhmkkdtsZBz8jp8afvRyfp1J0hbXidDSkzGYAEAYXWWhgmAeqS1ZVkuRYWSgtcc2C6sEJbWeFRtjxrQGo8nzWieE72XO_sS0JFiyQQwyWBCy5wWoEh1pWFrNJt09qEsDlQqpmsy30HjZWaNWo_VVij8tFVMboJeb-ctInOHbcP_-gRsAz1ttvhDQSjmsCo_gbGhFQzftTEYCIzwam62z_97Yw2hfe3f2gDzvbjpfIpXlXVyOoS8iLCcLnGApNNyXORkHTB5b-sdf9_rPUVue-njNLlA7I3XIz2NRK0Qb8J9-I14l9AvA priority: 102 providerName: Directory of Open Access Journals – databaseName: ScienceDirect Free & Delayed Access Titles dbid: IXB link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhUNoeSt_Z9IEKPdasLcu2dGxCQ1poL2lgb2ZkyYnLrm02Ns3-tf66zsgPuhRC6Um2kGTJM5JG9jffMPZeWpfFKM5AEDhMQlQG4EwalElo4igxsU3IUfjrt_T8Un5ZJasDdjr5whCsclz7hzXdr9ZjznJ8m8u2qpYXQuBJCrc_QkGSlY7rcCwVhW_4vDqZv7PgLJLCkxJQ-YAqTORDHuZFtJy3eE4UkvzPIxXvbVCex39vn_rbDn3I7vd1C7ufsF7_sTedPWaPRqOSfxz6_YQduPopuzeEmdw9Y78uGlv1mwmezoummynNt1zwqr6uTEVhdzixbdY92p98gqhyFKLH7XkRcrPjN307oGfrK-5q27RogG-qgnt_SPqYyD35Q1Xz7rpq_Mjx2jYbwISg8UNQCp7wKQJvx8nVpEFd9s2MmLENFnrOLs8-fT89D8aYDUEhs7ALhA0BNCiIjTHKCg2QJSJLtYiMcpA4kEaCMLFTxukUU13KsABtsL4oVPyCHdZN7Y4YVyWahig6DVKhXAGUtoVJHYSpKYvSLZiYBJUXI6E5xdVY5xNy7Ufux5iTdPNBugv2Ya7UDnwedxc_IQ2YixIZt89otlf5qI15BlbT_1yniczJAdgEe1qWRSRdFtpswdJJf_I93camqruf_m7SthxnPf3Kgdo1_U1OB780zdDWW7CXgxrOfYzxCKplpBYsmPXyX8Z6_L_dfMUe0N0AYn7NDrtt796gqdaZt34u_gYejUJH priority: 102 providerName: Elsevier – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFA46i4gP3i8VlQg-2qVN0zR5XMVlEVwEHVifysmlbnWmHXZadsef5q_zJG0HR2VZn1pKkiac0-RL853vEPKKW1dkaM6YeXIYh7SKwWkRV3miszTXmc19oPCHY3E05-9P8pNRZ9vHwuyc3wceltfNvMCNHOM-QBw98DrZEzkC7xnZmx9_PPji08exNIsRqRSTrtC_a-6sPUGif2cJ-hti3iI3-2YFm3NYLH5bdg7vDPHc66BW6Nkm3_f7Tu-bH39oOV5xRHfJ7RF-0oPBX-6Ra665T24MCSk3D8jPT62t--VEZKem7bbi52eU0bo5rXXtE_RQr8vZ9IhU6URmpWjuwPALxqZ6Q9f9auDZNl-pa2y7Qqi-rA0NkZP-tyMNMhF1Q7vTug0dxnvbLgEvnkQ_pK-gOZ1y9XbUB6W06PWhmZFdtsRCD8n88N3nt0fxmN0hNrxIupjZBECBhExrLS1TAEXOCqFYqqWD3AHXHJjOnNROCbyqiicGlMb6zMjsEZk1beOeECorBJG4d1XAJZfYrFTWaOEgEboylYsIm-xemlH63GfgWJQTx-1bGcZYeqOUg1Ei8npbaTUof1xe_I13qG1RL9sdHqDty3EWKAuwyp_8OuVlnxyAzbGnVWVS7orEFhERkzuWIwIakA02VV_-9peT85Y4P_hDH2hc269Lv0UUokBUGJHHg1dv-5jhZlXxVEYk3rr5Vcb69D_LPyOz7qx3zxG-dfrF-Nn-AtdXSag priority: 102 providerName: Unpaywall |
| Title | Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming |
| URI | https://dx.doi.org/10.1016/j.redox.2024.103183 https://www.ncbi.nlm.nih.gov/pubmed/38759418 https://www.proquest.com/docview/3056667910 https://doi.org/10.1016/j.redox.2024.103183 https://doaj.org/article/7ad92036e98041eaad59dcffc14e70d7 |
| UnpaywallVersion | publishedVersion |
| Volume | 73 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2213-2317 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884210 issn: 2213-2317 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVESC databaseName: ScienceDirect Free & Delayed Access Titles customDbUrl: eissn: 2213-2317 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884210 issn: 2213-2317 databaseCode: IXB dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2213-2317 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884210 issn: 2213-2317 databaseCode: DIK dateStart: 20130101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2213-2317 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884210 issn: 2213-2317 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 2213-2317 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884210 issn: 2213-2317 databaseCode: AKRWK dateStart: 20130101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2213-2317 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884210 issn: 2213-2317 databaseCode: RPM dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal - Open Access customDbUrl: eissn: 2213-2317 dateEnd: 20250831 omitProxy: true ssIdentifier: ssj0000884210 issn: 2213-2317 databaseCode: M48 dateStart: 20130201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFL0am4DxgPgc4aMyEo8EpYmT2A8IbYhpIG1CgkrlKbJjZwtqk65NxPrX-HXc6yRliDHxkkSV7Sa51_FxcnwOwCtubBphOP2QyGFcjQtfWZ34RRzoaBzryMS0UPj4JDma8E_TeLoFgytqfwNXV07tyE9qspy9uThfv8MO__Y3V4u0NS9wshdyWkSOWXoDdnCokuTlcNzjffdoFoLjHGdQH7q67i7cihDFS05GIJcGK6fp_8eY9TcmvQO322qh1j_UbHZpnDq8B3d7gMn2u4y4D1u2egA3O8vJ9UP4-aU2ZTsfqOosr5uNvPmShayszkpdkgUPI-XNqkUsyga6KsOAOg6fCyfTa7ZqFx2TtjpltjL1AsH4vMyZWxtJLxaZE4IoK9aclbW7CXhs6rnCHdHkO4MKFrPBjbdhtOykxrx2zfT8sTkWegSTww9f3x_5vX-Dn_M0aPzQBEpJJVSktRYmlEqlcZgmMhxrYVVsFddchTqyQluZ4F4WPMiV1Fg_zEX0GLarurJPgIkCYSJGTiouuMBmhTS5TqwKEl3khfUgHAKV5b24OXlszLKBxfY9c9eYUaCzLtAevN5UWnTaHtcXP6AM2BQlYW73Q708zfp-nqXKSPq2ayUJO1mlTIxnWhT5mNs0MKkHyZA_WY9xOuyCTZXX__vLIdsyfALQZx1V2bpdZTQJTJIUcZ8He10abs5xSGQP_E1e_s-1Pv1nS89gl8p1jOXnsN0sW_sCcVmjR-59Bm4_Tg9Grt-NYGdy8nn_2y_Z3j9V |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGENp4QNzGytVIPBI1cZzEfmQTU4FtL9ukvll27GxBbVJ1iaB_jV_HOc5FVEgT4ilVart2z7H9OfnOdwj5wK3LYjBnwJAcxnVUBNqZNCiS0MRRYmKbYKDw2Xk6u-Jf58l8hxwPsTBIq-zX_m5N96t1f2fa_5vTVVlOLxiDkxRsf8iCRJR-j9znCaATjOKbH40PWmAaceZVCbBCgDUG9SHP80Jdzp9wUGQcA9AjEW_tUF7If2uj-huIPiR7bbXSmx96sfhjczp5TB71qJJ-6jr-hOy46il50OWZ3Dwjvy5qW7bLgZ9O87oZNc3XlNGyuilNiXl3KMptVi0AUDpwVClY0RP3vA2p2dDbdtXRZ6tr6ipbrwCBL8uc-oBIfJpIvfpDWdHmpqz9yOGzrZcaLsiN77JS0IQOKXgbirEmNTizb6YnjS2h0HNydfL58ngW9EkbgpxnYRMwG2ottdCxMUZYJrXOEpalkkVGOJ04zQ3XzMROGCdTuMqCh7mWBuqzXMQHZLeqK3dIqCgAG4LppOaCC2hWSJub1OkwNUVeuAlhg6FU3iuaY2KNhRqoa9-VH6NC66rOuhPycay06gQ97i5-hB4wFkU1bn-jXl-r3h1Vpq3EF7pOopqT09om0NOiyCPustBmE5IO_qO2nBuaKu_-9feDtymY9vguR1eubm8VnvzSNAOwNyEvOjcc-xjDGVTySExIMPrlv4z15f928x3Zm12enarTL-ffXpF9_KZjNL8mu826dW8AtzXmrZ-XvwFX90Vt |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFA46i4gP3i8VlQg-2qVN0zR5XMVlEVwEHVifysmlbnWmHXZadsef5q_zJG0HR2VZn1pKkiac0-RL853vEPKKW1dkaM6YeXIYh7SKwWkRV3miszTXmc19oPCHY3E05-9P8pNRZ9vHwuyc3wceltfNvMCNHOM-QBw98DrZEzkC7xnZmx9_PPji08exNIsRqRSTrtC_a-6sPUGif2cJ-hti3iI3-2YFm3NYLH5bdg7vDPHc66BW6Nkm3_f7Tu-bH39oOV5xRHfJ7RF-0oPBX-6Ra665T24MCSk3D8jPT62t--VEZKem7bbi52eU0bo5rXXtE_RQr8vZ9IhU6URmpWjuwPALxqZ6Q9f9auDZNl-pa2y7Qqi-rA0NkZP-tyMNMhF1Q7vTug0dxnvbLgEvnkQ_pK-gOZ1y9XbUB6W06PWhmZFdtsRCD8n88N3nt0fxmN0hNrxIupjZBECBhExrLS1TAEXOCqFYqqWD3AHXHJjOnNROCbyqiicGlMb6zMjsEZk1beOeECorBJG4d1XAJZfYrFTWaOEgEboylYsIm-xemlH63GfgWJQTx-1bGcZYeqOUg1Ei8npbaTUof1xe_I13qG1RL9sdHqDty3EWKAuwyp_8OuVlnxyAzbGnVWVS7orEFhERkzuWIwIakA02VV_-9peT85Y4P_hDH2hc269Lv0UUokBUGJHHg1dv-5jhZlXxVEYk3rr5Vcb69D_LPyOz7qx3zxG-dfrF-Nn-AtdXSag |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sodium-glucose+cotransporter+2+inhibitors+attenuate+vascular+calcification+by+suppressing+endoplasmic+reticulum+protein+thioredoxin+domain+containing+5+dependent+osteogenic+reprogramming&rft.jtitle=Redox+biology&rft.au=Wu%2C+Shaofa&rft.au=Luo%2C+Xiaolin&rft.au=Chen%2C+Yang&rft.au=Wang%2C+Zelan&rft.date=2024-07-01&rft.eissn=2213-2317&rft.volume=73&rft.spage=103183&rft_id=info:doi/10.1016%2Fj.redox.2024.103183&rft_id=info%3Apmid%2F38759418&rft.externalDocID=38759418 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2213-2317&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2213-2317&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2213-2317&client=summon |